Actinic Keratosis Treatment Market - By Therapy (Photodynamic Therapy, Surgery, Topical), By Drug Class (NSAIDs, Nucleoside Metabolic Inhibitor), By End-use (Hospitals & Oncology Centers, Dermatology Clinics) & Forecast 2023 - 2032
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationActinic Keratosis Treatment Market - By Therapy (Photodynamic Therapy, Surgery, Topical), By Drug Class (NSAIDs, Nucleoside Metabolic Inhibitor), By End-use (Hospitals & Oncology Centers, Dermatology Clinics) & Forecast 2023 - 2032
Actinic Keratosis Treatment Market Size
Actinic Keratosis Treatment Market size accounted for USD 5.5 billion in 2022 and is estimated to grow at 5.5% to reach USD 9.7 billion by 2032. Rising prevalence of actinic keratosis coupled with growing demand for minimally invasive procedures.
For instance, according to American Academy of Dermatology Association 2019 report, more than 40 million Americans develop actinic keratoses (AKs) each year. Thus, increase in the prevalence of actinic keratosis is propelling the demand for minimally invasive procedures such as photodynamic therapy, thereby driving the market growth. Also, growing awareness pertaining to actinic keratosis and various strategic initiatives undertaken by key market players is expected to propel the market progression.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Actinic Keratosis Treatment Market Size in 2022 | USD 5.5 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 5.5% |
| 2032 Value Projection | USD 9.7 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 150 |
| Tables, Charts & Figures | 296 |
| Segments covered | Therapy, Drug Class, End-use, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
Actinic keratosis (AK) refers to a precancerous skin condition characterized by rough, scaly patches or lesions on areas of the body such as such as the face, scalp, ears, and hands that have been exposed to the sun. It is primarily caused by long-term ultraviolet (UV) radiation exposure from the sun or tanning beds. AK is considered a pre-malignant condition, meaning that if left untreated, it has the potential to progress into a type of skin cancer known as squamous cell carcinoma.
COVID-19 Impact
The COVID-19 pandemic severely impacted the global economies with all the sectors witnessing a significant slump during 2020. The healthcare sector was one of the most severely impacted sectors during the pandemic owing to tremendous pressure on the healthcare systems to contain the spread of infection. Increasing number of COVID-19 cases lead to a delay in non-essential procedures including various dermatological procedures including actinic keratosis treatment.
Also, several local and national regulatory bodies-imposed lockdowns, restricting the movement of people and goods. Thus, imposed lockdowns lead to disruption of supply chain and affected the availability of actinic keratosis treatment medications and equipment. Thus, significant delays in obtaining topical medications and actinic keratosis treatment negatively impacted the market growth trajectory.
Actinic Keratosis Treatment Market Trends
Exciting new treatments are popping up all the time for actinic keratosis, a skin condition caused by sun exposure. Just recently, Biofrontera AG got the green light from the FDA for their BF-RhodoLED XL. It teams up with Ameluz to fight mild to moderate actinic keratosis on your face and scalp. Sun Pharmaceutical Industries Ltd also has something newLEVULAN KERASTICK. This photodynamic therapy is approved to treat actinic keratosis on your arms and hands. With all these new options, doctors now have a bigger toolbox to choose from when treating actinic keratosis. This means better results and a brighter future for patients!
Actinic Keratosis Treatment Market Restrain
Actinic keratosis (AK) treatment options come with certain risks and side effects that may significantly impede the Actinic keratosis treatment industry growth. Treatments such as topical medications, cryotherapy, photodynamic therapy and surgical removal may possess risks such as skin irritation, redness, itching or discomfort at the treatment site.
Additionally, some treatments may result in temporary skin discoloration, scarring and infection. These potential side effects can impact patient satisfaction and adherence to treatment regimens. Furthermore, availability of alternative treatments such as generic medicine and availability of over-the-counter products and home remedies may impede the demand for prescription-based AK treatments.
Actinic Keratosis Treatment Market Analysis
When it comes to treating actinic keratosis, there are a few different options available. One of them is therapy, which can be broken down into three main typesphotodynamic therapy, surgery, and topical medications. Out of these, topical medications were the most popular choice in 2022, accounting for more than half of the market. And they're expected to keep growing in popularity over the next few years. Why? Because they're easy to use and can treat multiple areas at once, making them great for widespread or full-face treatments. Plus, they're non-invasive, which means they don't involve cutting or invasive procedures, and generally cause minimal disruption to your daily life. Some common topical medications for actinic keratosis include 5-fluorouracil (5-FU) and imiquimod. These are applied directly to the affected areas of the skin, providing targeted treatment.
Based on drug class, the market is segmented into NSAIDs, nucleoside metabolic inhibitor, immune response modifiers and photoenhancers. The nucleoside metabolic inhibitor is expected to register USD 3.1 billion in 2032. High segmental development is owing to the convenience of topical application that allows targeted delivery, minimizing systemic exposure to bloodstream and avoid potential side effects. Nucleoside metabolic inhibitor specifically target AK cell growth and proliferation by inhibiting nucleoside processes, leading to lesion regression. Also, clinical studies demonstrate their efficacy in reducing AK lesions, making them a beneficial option for managing actinic keratosis.
Actinic keratosis treatment market by end-use is market is divided into hospitals & oncology centers, dermatology clinics, homecare and others. The hospitals & oncology centers accounted for significant market proportion in 2022 and is expected to grow at 5.7% throughout the forecast period. Hospitals & oncology centers offer a wide range of treatment options for actinic keratosis including surgical interventions, cryotherapy, topical medications, photodynamic therapy among others.
Also, availability of multiple treatment alternatives allows healthcare providers to opt for most appropriate, suitable approach based on factors such as lesion characteristics, patient preferences and medical considerations. Furthermore, availability of skilled healthcare professionals, advanced healthcare infrastructure among others is projected to boost the market revenue.
Actinic keratosis, a skin condition caused by sun damage, is a big issue in North America. In 2022, treatments for this condition made up over 40% of the market. And this market is expected to keep growing at a good pace in the coming years. There are a few reasons for this growth. First, more and more people are getting actinic keratosis. Second, the healthcare system in North America is well-equipped to treat this condition. Third, people are becoming more aware of the risks of sun exposure and are getting their skin checked more often. This is leading to earlier diagnosis and treatment of actinic keratosis. Another factor that's helping the market grow is the presence of major pharmaceutical companies in North America. These companies are developing new and innovative treatments for actinic keratosis. And finally, insurance coverage for actinic keratosis treatments is good in North America, which makes it easier for people to afford the treatment they need.
Actinic Keratosis Treatment Market Share
Major market players operating in the actinic keratosis treatment market include
- Sun Pharmaceutical Industries Ltd
- Galderma S.A.
- Biofrontera AG
- Almirall, S.A.
These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
Actinic Keratosis Treatment Industry News
- In December 2022, Biofrontera AG commercially launched AMELUZ in Finland. This product launch can be used in line with the European approval for the treatment of actinic keratoses and basal cell carcinoma with the BF-RhodoLED lamp as part of conventional photodynamic therapy or as daylight therapy. This strategy helped the company enhance its product offerings as well as strengthen its geographical presence in the Europe region.
- In December 2020, Almirall received FDA approval for Klisyri (tirbanibulin), a new innovative topical treatment for actinic keratosis. This product approval helped the company to enhance its actinin keratosis product portfolio and reach untap economies, thereby increase customer base.
The actinic keratosis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments
Click here to Buy Section of this Report
By Therapy
- Photodynamic Therapy
- Surgery
- Topical Medications
By Drug Class
- NSAIDs
- Nucleoside Metabolic Inhibitor
- Immune Response Modifiers
- Photoenhancers
By End-use
- Hospitals and Oncology Centers
- Dermatology Clinics
- Homecare
- Others
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Poland
- Sweden
- The Netherlands
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Indonesia
- Philippines
- Malaysia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Columbia
- Chile
- Peru
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Iran
- Rest of MEA
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy